Lv3
330 积分 2024-07-23 加入
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
25天前
已完结
Frauenfeld L, et al.Advances in the Classification of Aggressive B-cell Lymphomas
29天前
已完结
338 Randomized Phase Ill Study of Watchful Waiting Vs.Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma:JCOG1411/Flora Study
1个月前
已完结
Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study
1个月前
已关闭
2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies
1个月前
已完结
MRD-guided zanubrutinib, venetoclax and obinutuzumab in relapsed CLL: primary endpoint analysis from the CLL2-BZAG trial
2个月前
已完结
Diagnosis and Treatment of Polycythemia Vera
2个月前
已完结
Treatment Patterns and Outcomes in Follicular Lymphoma with POD24: An Analysis from The LEO Consortium
3个月前
已完结
MRD-negative duration following latest line of therapy predicts long-term PFS in real-world multiple myeloma patients
3个月前
已关闭
皖公网安备34019202002308
